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Neuroinflammation and brain functional disconnection result from β-amyloid (Aβ) accumu-
lation and play fundamental roles in the pathogenesis of Alzheimer’s disease (AD). We
investigated possible correlations between these two AD-associated phenomena using
DTI-based tractography and immunologic analyses in people with amnestic mild cognitive
impairment (aMCI) and AD. DTI-Analyses focused on corpus callosum (CC). We found that
frontal CC regions were preserved with respect to the posterior ones in aMCI; in these indi-
viduals significant correlations were seen between DTI-derived metrics in frontal-parietal
CC areas and Aβ42-stimulated BDNF-producing CD4+T lymphocytes and PDL-1-expressing
CD14+ cells. These associations were lost in AD where DTI data involving the same CC
areas correlated instead with Aβ42-stimulated interleukin (IL)-21 producing CD4+ T lym-
phocytes. Higher susceptibility to PDL-1-mediated apoptosis of Aβ42-specific lymphocytes
and BDNF-associated survival of existing neurons could contribute to the relative CC struc-
ture preservation seen in aMCI. These potentially protective mechanisms are lost in frank
AD, when severe alterations in the CC are mirrored in peripheral blood by proinflammatory
cytokines-producing T cells. Monitoring of immune cells in peripheral blood could have a
prognostic value in AD.
Keywords:Alzheimer’s disease, mild cognitive impairment, magnetic resonance imaging, diffusion tensor imaging,
immunology, neuroinflammation
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder involv-
ing both gray matter (GM) and white matter (WM) tissues that is
now well defined as a part of a continuum of clinical and biological
phenomena. AD is characterized by the accumulation of amyloid-
beta (Aβ) peptide into amyloid plaques in the extracellular brain
parenchyma and by the formation of neurofibrillary tangles (NFT)
within neurons as a result of the abnormal phosphorylation of
the microtubules-associated tau-protein. Neuroinflammation is
strongly suspected to play an important role in AD that might
be the culprit of the disease or, possibly, a reaction to the pathol-
ogy (Ke et al., 2006; Zipp and Aktas, 2006). Thus, both increased
concentrations of proinflammatory cytokines (Bauer et al., 1991;
Strauss et al., 1992; Remarque et al., 2001; Bermejo et al., 2008) and
changes in lymphocyte subsets, with an augmented percentage of
activated immune cells are described in AD (Lombardi et al., 1999;
Speciale et al., 2007; Saresella et al., 2011). In particular, recent
results indicated that a significant reduction of PD-1- and PDL-
1-expressing cells is present in AD and amnestic mild cognitive
impairment (aMCI), a prodromal stage of AD. The interaction
between these molecules is responsible for the induction of tol-
erance and for the apoptosis of antigen-specific cells (Francisco
et al., 2010); as the impairment seen in AD and aMCI is specific
for Aβ-stimulated cells, this alteration could play a role in the
neuroinflammation accompanying AD (Saresella et al., 2012).
Functional disconnection as a consequence of Aβ pathology
has also recently been hypothesized to be a major mechanism in
AD clinical evolution (Drzezga et al., 2011). This suggestion stems
from the evidence that WM damage can be observed even in AD
patients in early stages of disease, and this correlates with clinical
measures of cognitive disability (Parente et al., 2008; Bozzali et al.,
2011). DTI-based tractography is an ideal MRI based technique
for the study of WM changes in the most relevant fiber bundles
of the brain (Le Bihan, 2003), and DTI results of previous studies
confirmed that brain disconnection plays an important role in AD
pathophysiology, and contributes to the progressive accumulation
of disabilities in the transitional stage between normal aging and
dementia (Bozzali et al., 2002, 2011; Takahashi et al., 2002; Duan
et al., 2006; Naggara et al., 2006; Zhang et al., 2007; Serra et al.,
2010; Gili et al., 2011).
The corpus callosum (CC), the largest WM fiber connection
of the human brain, is an ideal target to test physiopathological
changes in AD. In a previous DTI-study (Preti et al., 2012), we
investigated the pattern of CC abnormalities in different stages
of AD and showed the presence of an early selective damage of
the central and posterior CC subregions in this disease. This CC
damage pattern is consistent both with the distribution of GM loss
found in volumetric studies (Karas et al., 2008; Kakeda and Korogi,
2010; Vemuri et al., 2011), and with the neuropsychological profile
of the patients (Leube et al., 2008; Risacher et al., 2009; Serra et al.,
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2010). These alteration are also consistent with the pathological
knowledge that we have of AD progression, according to which the
posterior CC subregions are preferentially involved in the earlier
stages of AD whereas and the anterior CC subregions are usually
affected in the later stages of disease (Brun and Englund, 2002).
We investigated possible correlations between neuroinflamma-
tory parameters and brain disconnection in AD and aMCI using
DTI-based tractography and immunologic analyses performed on
peripheral blood mononuclear cells. In particular, the CC was
evaluated in its different parts to identify the anatomical regions
in which the damage mediated by inflammation plays a promi-
nent role, and immunologic studies were performed in peripheral
blood in the attempt to identify easily reproducible diagnostic
and/or prognostic parameters.
MATERIALS AND METHODS
SUBJECTS
Forty patients diagnosed with probable AD according to the
NINCDS-ADRDA criteria (McKhann et al., 2011) and 20 sub-
jects diagnosed with aMCI according to Petersen criteria (Petersen,
2004) were included in the study. All subjects were consecutively
recruited at the Fondazione Don Gnocchi, IRCCS in Milano, Italy.
AD patients were in mild stage of the disease as determined by
both clinical dementia rating (CDR) (Morris, 1993) scale (CDR
range 0.5–1.5) and mini-mental state examination score (Magni
et al., 1996) (MMSE mean/SD 20.2/2.7). To be eligible for the
study, aMCI individuals were required to meet the Grundman
operational criteria (Grundman et al., 2004): memory complaint,
confirmed by an informant; abnormal memory function, doc-
umented by previous extensive neuropsychological evaluation;
normal general cognitive function, as determined by both CDR
scale (Morris, 1993) (CDR with at least a 0.5 in the memory
domain) and MMSE (Magni et al., 1996) score (MMSE greater
than or equal to 24); no impairment in functional activities of
daily living as determined by a clinical interview with the patient
and informant; no significant cerebral vascular disease (Hachinski
score less than or equal to 4) (Rosen et al., 1980); no major psy-
chiatric illnesses with particular attention to exclude subjects with
history of depression (Hamilton Depression Rating Scale score
less than or equal to 12) (Hamilton, 1960). To increase the diag-
nostic accuracy analyses of hippocampal volumes, an index of
downstream neural injury according to the guidelines for MCI
due to Alzheimer’s dementia (Sperling et al., 2011), were also
included in the study. Demographic details of the study sample are
summarized in Table 1. Twenty-five healthy controls (CTRs) that
were age-and sex-matched to the AD patients (70.2± 5.1 years;
11M/14F; MMSE score >26) were also included in the MR analy-
sis for the tractographic atlas construction. The study conformed
to the ethical principles of the Helsinki Declaration; all patients
or their care-givers gave informed consent according to a proto-
col approved by the local ethics committee of the Don Gnocchi
Foundation.
MRI ACQUISITIONS AND ANALYSES
MRI acquisition protocol
Brain MR images were acquired using a 1.5-T scanner
(Siemens Magnetom Avanto, Erlangen, Germany). The following
Table 1 | Demographical and anatomical information of the sample.
AD aMCI CTR
N 40 20 25
Age [years, mean (SD)] 73.7 (12) 73.9 (5.4) 70.2 (5.1)
Sex (M:F) 17:23 12:8 11:14.
MMSE score [mean (SD)] 20.2 (2.7) (§) 25.6 (1.7) (∧) 29.1 (0.7) (#)
CDR (range) 1–1.5 (§) 0–0.5 0
Right hippocampal
volume [mm3, mean (SD)]
2898 (575) (§) 3158 (519) (∧) 3774 (558) (#)
Left hippocampal volume
[mm3, mean (SD)]
2719 (482) (§) 3065 (489) (∧) 3607 (450) (#)
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; CTR, healthy
controls; MMSE, mini-mental state evaluation; CDR, clinical dementia rating
scale; SD, standard deviation. Chi-squared test was used for gender compari-
son and one-way ANOVA with Bonferroni post hoc test was used for age, MMSE
score and hippocampal volumes comparisons (significance level: p<0.05). (#)
Significant compared to MCI and AD group; (§) significant compared to MCI and
CTR; (∧) significant compared to AD and CTR.
sequences were acquired: (1) dual-echo turbo spin echo
(TR/TE= 2920/22 ms, FoV= 240 mm× 180 mm, in-plane reso-
lution= 0.75 mm× 0.75 mm, slice thickness= 4 mm, number of
axial slices= 25) and FLAIR sequence (TR/TE= 9000/121 ms,
FoV= 240× 168 mm, in-plane resolution= 0.94 mm× 0.94 mm,
slice thickness= 5 mm, number of coronal slices= 24), to exclude
patients showing WM hyperintensities outside the normal
range; (2) three-dimensional T1-weighted magnetization pre-
pared rapid gradient echo (MPRAGE) (TR/TE= 1900/3.37 ms,
FoV= 192 mm× 256 mm, in-plane resolution 1 mm× 1 mm,
slice thickness= 1 mm, number of axial slices= 176); (3)
diffusion-weighted pulsed-gradient spin-echo planar (TR/TE=
7000/94 ms, FOV= 320 mm× 240 mm, in-plane resolution=
2.5 mm× 2.5 mm, slice thickness= 2.5 mm, number of axial
slices= 50), with diffusion gradients (b-value= 900s/mm2)
applied in 12 non-collinear directions. Two runs of DW images
with one b= 0 image without diffusion weighting were acquired
for each subject.
Analysis of T1-weighted structural images
Two different analyses were performed on the T1-weighted struc-
tural images in order to provide further information about the
underline pathology in this cohort of subjects: (1) computation
of hippocampal volumes; (2) voxel-based morphometry (VBM)
analysis.
Hippocampal volume data were extracted for each subject from
high-resolution T1 3D images. Segmentation of right and left
hippocampi was performed using FSL’s FIRST method (Pate-
naude et al., 2011), an approach combining both shape and
intensity information within a Bayesian Model to segment sub-
cortical structures. After hippocampal segmentation, volumetric
data had been obtained in each subject using a specific FSL
function.
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The VBM analysis was conducted using VBM81, toolbox of
SPM82, running on Matlab 7.6.03. VBM was conducted according
to the Unified Method (Ashburner and Friston, 2005). After GM
segmentation all images underwent spatial smoothing using a
Gaussian kernel (FWHM 8 mm).
Analysis of diffusion-weighted images
Diffusion-Weighted Images (DWI) were first corrected for eddy
current distortions, using FSL4. For every subject, the images of
the second run were registered to the first one using SPM5 (see text
footnote 2). The affine transformation between the b= 0 image
of the second run and the b= 0 image of the first one was esti-
mated and applied to all the DWI of the second run. From the
DWI, the diffusion tensor (DT) and its scalar invariants fractional
anisotropy (FA) and mean diffusivity (MD) were computed for
every voxel, using Diffusion Toolkit5 v0.6, which firstly rotates the
B-matrix for slice angulation and for the rotation applied by FSL
and SPM.
CC tractographic analysis
To assess CC integrity, the atlas-based tractography method
described in Preti et al. (2012) was adopted. For the atlas con-
struction, individual deterministic tractography of the CC was
performed for the CTRs with Diffusion Toolkit, using all voxels as
seed points (brute force approach) and the Interpolated Stream-
line algorithm. FA and angle thresholds of 0.2 and 35° respectively
were adopted as stopping criteria for the tractographic algorithm.
The tracts of seven CC regions portions (CC1: orbital frontal,
CC2: anterior frontal, CC3: superior frontal, CC4: superior pari-
etal, CC5: posterior parietal, CC6: temporal, CC7: occipital) were
selected from the whole brain tracts by drawing regions of interest
(ROIs) on the FA map using Trackvis v0.5.1 (see text footnote 6)
and following the ROI positioning suggested by Lebel et al. (2010).
From the individual tractographic reconstructions, the probabilis-
tic atlases of the seven CC portions were obtained, adopting the
method described in detail in Preti et al. (2012).
Average FA and MD values along the tracts in the seven CC por-
tions (CC1–CC7) were extracted for every subject basing on the
locations given by the created tractographic atlases. First, all sub-
jects were linearly registered to the atlas space with FSL, using the
FMRIB58_FA as template for the alignment. Then, the estimated
transformation between individual FA maps and the template was
applied to both FA and MD maps of every subject. Finally, the
registered FA and MD maps of all subjects were masked with the
atlases and, for each tract portion, the index mean values weighted
for the probability given by the atlas were computed.
IMMUNOLOGICAL ANALYSES
Blood sample collection and cell culture
Whole blood was collected in vacutainer tubes containing eth-
ylenediaminetetraacetic acid (EDTA) (Becton Dickinson & Co.,
1http://dbm.neuro.uni-jena.de/vbm/
2http://www.fil.ion.ucl.ac.uk/spm/
3http://www.mathworks.it/products/matlab
4http://www.fmrib.ox.ac.uk/fsl/
5www.trackvis.org
Rutherford, NJ, USA). PBMC were separated on lympholyte
separation medium (Cedarlane, Hornby, ON, Canada); viable
leukocytes were determined using a Scepter 2.0 Handheld Auto-
mated Cell Counter (Millipore, Billerica, MA, USA).
About 1× 106 PBMC were cultured for 24 h in RPMI
1640+ 10% human serum, 2 mM l-glutamine, and 1% penicillin
(Invitrogen Ltd, Paisley, UK) with either non-immunogenic pep-
tides (Saresella et al., 2008) or with 10µg/ml of Aβ42-peptide
soluble monomer (Sigma, St Louis, MO, USA) at 37°C in a humidi-
fied 5% CO2 atmosphere for 24 h. The dose of peptides was chosen
based on previously results (Saresella et al., 2010). For cytokine
analyses, 10µg/ml of brefeldin A (Sigma-Aldrich) was added to
the cell cultures during the last 6 h of stimulation to block protein
secretion.
Flow-cytometry immunofluorescent staining
Aβ42-peptide – or non-immunogenic peptides-stimulated PBMC
were resuspended in PBS and stained with anti-CD4, -CD8, -
CD19, -CD14, -PD-1, or -PDL-1 specific mAbs (eBioscience, San
Diego, CA, USA). Cells were washed after 30 min incubation at
room temperature in the dark, treated with FIX and PERM (FIX
and PERM Cell Permeabilization kits; eBioscience) and incubated
for 30 min at 4°C in the dark with cytokine-specific mAbs.
The following mAbs were used: phycoerythrin (PE)-Cyanin-7
(PC7)-labeled-anti-CD4 (clone SFCI12T4D11; mouseIgG1), PE-
Cyanin-5 (PC5)-labeled-anti-CD8 (clone SFC12Thy2D3; mouse-
IgG1), PC5-labeled-anti-CD19 (clone J4.119; mouse IgG1),
and PC7-labeled-anti CD14 (clone RMO52, mouse IgG2a,
Beckman-Coulter Brea, CA, USA); PE-labeled-anti-PD-1 (clone
MIH4; mouse-IgG1) and (PC5)-labeled-anti-PDL-1 (clone MIH1;
mouse-IgG1; eBioscience Cornerstone Court, West, San Diego,
CA, USA). The intracellular molecule detection mAbs used were:
PE-labeled-anti-interleukin (IL)-6 (clone 1936, mouse IgG2B),
PE-labeled-anti-IL-10 (clone JES9D7; mouse IgG1), PE-labeled-
anti-IL-22 (clone 142928, mouse IgG1), Fluorescein isothio-
cyanate (FITC)-labeled-anti-IL-12 (clone 27537, mouse IgG1),
PE-labeled-anti-TGF-β- (clone 9016, mouse IgG1), PE-labeled-
anti-IFNγ (clone 25723, mouse IgG2b), and PE-labeled-anti-
BDNF (clone 35909; mouse-IgG1 R&D Systems, Inc., Min-
neapolis, MN, USA); PE-labeled-anti-IL-9 (clone MH9A4, mouse
IgG2B,k), PE- labeled-anti-IL-23 (clone C11.5, mouse IgG1k),
and PC5-labeled-anti-IL-17 (clone BL168, mouse IgG1k; Biole-
gend San Diego, CA, USA); PE-labeled-anti-ROR-C/γ (clone
AFKJS-9, rat IgG2a), PE-labeled- anti T-bet- (clone 39D,
mouse IgG1), PE-labeled-anti-GATA-3 (cloneTWAY, rat IgG2B,k),
and PE-labeled-anti-IL-21 (clone 3A3-N2, mouse IgG1; Bio-
science).
Flow-cytometry analysis
A Beckman-Coulter Cytomics FC-500 flow cytometer equipped
with a single 15 mW argon ion laser operating at 488 nm and inter-
faced with CXP Software 2.1 was used. Two-hundred-thousand
events were acquired and gated on lymphocyte or monocyte FSC
and SSC properties. Samples were first run using isotype control
or single fluorochrome-stained preparations for color compensa-
tion. Rainbow Calibration Particles (Spherotec, Inc. Lake Forest,
IL, USA) were used to standardize flow-cytometry results.
Frontiers in Aging Neuroscience www.frontiersin.org November 2013 | Volume 5 | Article 81 | 3
Baglio et al. Neuroinflammation and brain disconnection in AD
STATISTICAL ANALYSIS
The statistical analyses were accomplished using commercial soft-
ware (SPSS for Windows, V 18.0; SPSS Inc). We compared aMCI,
AD, and CTRs on demographic data, using the chi-square test
and one-way ANOVA with Bonferroni post hoc test for categorical
and dimensional variables, respectively. To test the comparisons
between the aMCI and AD groups, Mann–Whitney U - or t -test
were performed and continuous variables were described using
median and interquartile range, according to variable skewness.
The statistical correlations between immunological parameters
and RM data were investigated by means of Spearman correla-
tion coefficient and 95% confidence limits performed by Fisher’s
Z transformation.
RESULTS
DEMOGRAPHICAL AND ANATOMICAL CHARACTERISTICS OF THE
PARTICIPANTS
CTRs, aMCI subjects, and AD patients were comparable for age
and gender; a significant difference was found instead for MMSE
and CDR values, accordingly with the adopted inclusion criteria
(Table 1).
Structural MRI confirmed the pattern of GM atrophy typ-
ical of aMCI and AD. VBM showed that patients with AD
were significantly more atrophic than aMCI in several brain
regions including medial, anterior, and postero-inferior regions
of temporal lobes (left> right) and precuneus/posterior cingulate
(Figure 1). Hippocampal volumes of CTRs were significantly dif-
ferent compared to aMCI and AD (p< 0.05 Bonferroni post hoc ;
CTRs> aMCI>AD).
DTI ANALYSES
Significantly reduced FA values were found in the frontal CC
regions (CC2–CC3) of AD compared to aMCI subjects (p< 0.01).
Moreover, MD values were significantly higher in AD with respect
to aMCI group, in every portion with the exception of CC7. Results
of the comparison between mean FA/MD computed in the seven
CC portions of the two groups (aMCI and AD patients) are showed
in Table 2 and Figure 2.
IMMUNOLOGICAL RESULTS
Cytokine-producing and transcription factor-expressing T cells in
Aβ42-peptide-stimulated cell cultures
PBMC obtained from AD and aMCI patients were stimulated
in vitro with either Aβ42-peptide or with non-immunogenic
control peptides. Cytofluorimetric analyses were used to ana-
lyze IFNγ-, IL-9-, IL-17-, IL-21-, IL-22-, and BDNF-producing
CD4+ and CD8+ T lymphocytes. Results showed that, whereas
no differences were seen when cells were stimulated with
non-immunogenic peptides (data not shown), Aβ42-stimulated-
BDNF-producing CD4+ T lymphocytes were significantly
reduced in AD compared to aMCI (p= 0.003); interestingly,
and confirming the increased inflammatory status of AD, IFNγ-
producing-CD8+ T lymphocytes were increased in AD compared
to AMCI individuals (p= 0.012).
Distinct transcription factors (TF) are activated during the
differentiation of T cells into functional subsets. We analyzed
T-Bet, ROR-C/γ and GATA-3 TF in all the individuals enrolled
in the study. Results show an increase of Aβ42-stimulated-
CD8+ T cells expressing T-bet in AD compared to aMCI
(p=<0.001). As T-bet is the TF expressed by cells that have
differentiated into TH1 lymphocytes, and because such lympho-
cytes are characterized by the production of IFNγ, these results
explain the increased production of this cytokine seen in AD
(Table 3).
Table 2 | Results of DTI-based tractography.
aAMCI AD Comparison
aMCI-AD (*)
CC
portion
FA MD FA MD FA MD
Mean
(SD)
Mean
(SD)
Mean
(SD)
Mean
(SD)
p
value
p
value
CC1 0.47 (0.06) 0.86 (0.11) 0.45 (0.06) 0.94 (0.10) n.s. 0.013
CC2 0.59 (0.06) 0.90 (0.09) 0.54 (0.07) 0.98 (0.11) 0.009 0.012
CC3 0.52 (0.06) 0.97 (0.07) 0.49 (0.05) 1.04 (0.09) 0.021 0.018
CC4 0.50 (0.07) 1.04 (0.11) 0.48 (0.07) 1.12 (0.13) n.s. 0.034
CC5 0.58 (0.08) 0.93 (0.09) 0.54 (0.08) 1.03 (0.15) n.s. 0.009
CC6 0.59 (0.09) 1.01 (0.20) 0.57 (0.09) 1.13 (0.24) n.s. 0.039
CC7 0.54 (0.10) 0.97 (0.15) 0.53 (0.10) 1.03 (0.13) n.s. n.s.
Comparison between DTI-metrics (mean FA/MD) computed in the seven CC por-
tions of the two groups (aMCI and AD patients).
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; CC, corpus
callosum; FA, fractional anisotropy; MD, mean diffusivity. (*) p-values refer to
t-test, significance level p<0.05
FIGURE 1 | VBM results. AD patients were found to be significantly more atrophic than aMCI in medial, anterior, and postero-inferior regions of temporal lobes
(left> right) and precuneus/posterior cingulate.(FDR<0.05)
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FIGURE 2 | Comparison of fractional anisotropy (FA) values between aMCI and AD patients in the seven portions of the corpus callosum (CC).
Significant differences between the two groups were found only in two frontal CC portions (CC2 and CC3). (*p<0.05).
Cytokine-producing CD14+ cells in Aβ42-peptide-stimulated cell
cultures
The immune response is mediated by multiple cell types. To bet-
ter approach the in vivo situation we examined IL-6-, IL-10-,
IL-12p35-, IL-23-, and TGFβ-expressing CD14+ monocytes in
peripheral mononuclear cell cultures that had been stimulated
with the non-immunogenic or with the Aβ42-peptide. Results
indicated that Aβ42-stimulated TGF-β-producing CD14+ cells
were significantly decreased in AD compared to aMCI (p= 0.003)
(Table 3).
PD-1-expressing CD4+ and CD8+ T lymphocytes and
PD-L1-expressing CD14+ and CD19+ cells in
Aβ42-peptide-stimulated PBMC
PD-1 on T lymphocytes binds PD-L1 on the surface of anti-
gen presenting cells (APC) resulting in the dampening of adap-
tive immune-response via tolerization or apoptosis of antigen-
specific T lymphocytes. Aβ42-stimulated lymphocytes and mono-
cytes (APC) were analyzed in PBMC isolated from the peripheral
blood of patients. Results showed that both PD-1- and PD-L1-
expressing cells were reduced in AD compared to aMCI indi-
viduals, even if the differences did not reach statistical signifi-
cance (Table 3). Again, no differences were observed when cells
were incubated with the non-immunogenic peptides (data not
shown).
CORRELATIONS BETWEEN MRI AND IMMUNOLOGIC PARAMETERS
Correlations were sought between the FA values that were sig-
nificantly different between groups (CC2–CC3) and immuno-
logical parameters; separate analyses were performed for each
group. Results showed significantly positive correlations in aMCI
between the FA values for both CC2 and CC3 and circulating Aβ42-
stimulated CD4+/BDNF+, CD8+/BDNF+, and CD14+/PD-
L1+ cells (Table 4). These correlations were not maintained in AD
patients in whom, instead, an important positive correlation was
detected between the CC2 FA and Aβ42-stimulated CD4+/IL-21+
(inflammatory) lymphocytes (RSp=−0.41).
DISCUSSION
We investigated possible interactions among peripheral immuno-
logical parameters and brain disconnection in AD and aMCI
individuals using DTI-based tractography. Analyses on brain dis-
connection focused on the CC, which appears as an ideal candidate
for the investigation of WM damage in the different stages of
the AD disease, due to its particular susceptibility to atrophy
(Thomann et al., 2006; Chaim et al., 2007). This structure was
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Table 3 | CD4+, CD8+, and CD14+ cells that produce cytokines and
CD4+, CD8+, CD14+, and CD19+ cells that express PD-1 or PD-L1 in
patients with a diagnosis of either AD or aMCI.
aMCI AD p-value (*)
CD4+GATA-3+ 0.40 (0.00−1.25) 0.05 (0.00−0.70) n.s.
CD4+ROR-C-γ+ 0.16 (0.07−0.40) 0.10 (0.00−0.38) n.s.
CD4+IFNγ+ 0.10 (0.01−0.32) 0.15 (0.00−0.40) n.s.
CD4+IL-17+ 0.05 (0.00−0.08) 0.07 (0.00−0.29) n.s.
CD4+IL-9+ 0.12 (0.04−0.40) 0.10 (0.02−0.22) n.s.
CD4+IL-21+ 0.01 (0.00−0.73) 0.30 (0.02−0.62) n.s.
CD4+IL-22+ 0.20 (0.10−0.50) 0.42 (0.10−0.70) n.s.
CD4+BDNF+ 0.39 (0.27−0.58) 0.12 (0.03−0.29) 0.003
CD8+BDNF+ 0.45 (0.18−1.71) 0.31 (0.13−0.55) n.s.
CD8+T-bet+ 0.01 (0.00−0.05) 1.22 (0.09−3.16) <0.001
CD8+IFNγ+ 0.02 (0.00−0.065) 0.065 (0.01−0.15) 0.0127
CD14+TGF-β+ 5.50 (2.27−16.05) 1.87 (0.53−3.05) 0.003
CD14+IL-6+ 15.50 (1.27−38.77) 10.11 (2.20−16.00) n.s.
CD14+IL-10+ 3.95 (2.43−13.88) 2.05 (0.53−12.82) n.s.
CD14+IL-12p35+ 0.6 (0.00−1.82) 0.18 (0.02−1.4) n.s.
CD14+IL-23+ 2.5 (0.92−4.49) 1.4 (0.47−2.56) n.s.
CD4+PD-1+ 0.38 (0.00−2.67) 0.31 (0.1−2.10) n.s.
CD8+PD-1+ 0.06 (0.00−0.09) 0.04 (0.02−0.15) n.s.
CD19+PD-L1+ 0.05 (0.00−0.07) 0.02 (0.00−0.08) n.s.
CD14+PD-L1+ 1.20 (0.30−3.34) 0.55 (0.28−1.10) n.s.
Percentages of Aβ42-stimulated cells are shown; median, interquantile ranges,
and statistical significance are indicated.
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; IL, inter-
leukin; BDNF, brain-derived neurotrophic factor; ROR, retinoid acid-related orphan
receptor; T-bet, T-box expressed inT cells; IFN-γ, interferon-gamma;TGF- β, trans-
forming growth factor-beta; PD-1, programed death-1; PD-L1, programed death-1
ligand.
(*) p-Values refer to Mann–Whitney-U, significance level p< 0.05.
In all cases, background results (i.e., % of cytokines secreting or PD-expressing
cells in PBMC incubated with non-immunogenic peptides) were subtracted from
the values shown.
evaluated in its seven different parts, allowing the definition of a
valued topographic distinction of WM damage in different stages
of AD pathology.
MRI results showed that different WM damage pattern are seen
in aMCI and AD. Thus DTI analysis on FA indicated that the
frontal CC subregions are preserved in the prodromal stage of
the pathology (higher FA values on FA CC2–CC3 in aMCI), and
MD values were still preserved in aMCI in almost the whole CC
(higher MD values in AD only in CC7). This appears interest-
ing when considering the different type of information provided
by the two DTI indices: MD is more fit at analyzing extracellu-
lar volume alterations whereas FA better investigates impairments
in the axonal integrity (Werring et al., 1999; Rovaris et al., 2005),
independently of the gross tissue loss (Burzynska et al., 2010).
When these indexes are analyzed together, lower FA and higher
MD values suggests a loss of cortical regions related to the phe-
nomenon of the anterograde Wallerian degeneration (Xie et al.,
2006; Damoiseaux et al., 2009) whereas areas characterized by
lower FA without particular changes on MD indicate the presence
Table 4 | Correlations between MRI (DTI-metrics) and immunological
parameters.
Variable With variable RSp (95% C.L.) P value
aMCI
FA_CC2 CD14+/PD-L1+ 0.53 (0.01; 0.82) 0.0389
FA_CC3 CD14+/PD-L1+ 0.66 (0.21; 0.87) 0.0057
FA_CC2 CD4+/BDNF+ 0.64 (0.08; 0.88) 0.0226
FA_CC3 CD4+/BDNF+ 0.62 (0.05; 0.88) 0.0284
FA_CC2 CD8+/BDNF+ 0.69 (0.16; 0.90) 0.0116
FA_CC3 CD8+/BDNF+ 0.81 (0.40; 0.94) 0.0008
AD
FA_CC3 CD4+/IL-21+ −0.41 (−0.68; −0.02) 0.0346
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; CC, corpus
callosum; FA, fractional anisotropy; RSp, Spearman correlation coefficient and 95%
confidence limits performed by Fisher’s Z transformation.
of a possible myelin breakdown process related to amyloid and
tau deposits (Bartzokis, 2011; Lu et al., 2013). Results herein indi-
cate that in aMCI brain disconnection mechanism are mainly due
to myelin breakdown (lower FA without increase in MD). Inter-
estingly, this process is located in almost the whole CC with the
exclusion of frontal and parietal CC regions. This finding appears
in line with previous results (Parente et al., 2008; Di Paola et al.,
2010; Agosta et al., 2011; Preti et al., 2012), describing AD as part
of a continuum of clinical and biological phenomena with a pos-
terior to anterior pathophysiological evolution. This early damage
of the posterior CC subregions in AD reflects the accumulation of
proteinaceous deposits, such as Aβ and tau, involving initially the
medial-temporal regions (Brun and Englund, 2002). These results
are consistent with MRI-GM structural data and with the well-
known pattern of distribution of neuropathological changes typi-
cal of AD neurodegeneration, which starts from medial-temporal
regions then spreads to medial-parietal cortex and orbitofrontal
regions and finally to other neocortical association areas (Busatto
et al., 2008).
Results of immunological analyses performed in the same indi-
viduals showed that, upon Aβ42-stimulation, BDNF-producing
CD4+ and TGF-β-producing CD14+ were significantly reduced,
whereas IFNγ-producing and T-bet expressing CD8+ T cell were
increased in AD compared to aMCI. These immune alterations
were detected only in vitro Aβ42-stimulated cell cultures suggest-
ing that they are specific for the aMCI-AD spectrum. TGF-β
and BDNF are cytokines endowed with anti-inflammatory and
neuroprotective function, even though recently these roles have
become ambiguous. In particular TGF-β is a pleiotropic cytokine
characterized by mutually exclusive regulatory and inflammatory
activities that are cellular and environmental-context dependent.
When the inflammatory properties prevail, TGF-β induces the
differentiation of TH17 cells (Sanjabi et al., 2009). The observa-
tion that in aMCI TH17-produced cytokines (IL-17, IL-21, IL-22)
were not detected seems to indicate that the biological significance
of the increased production of TGF- β seen in these patients is
anti-inflammatory. In AD the recruitment of peripheral mono-
cytes/macrophages within the CNS could contrast the formation
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and/or reduce the extension of β-amyloid plaques via multiple
mechanisms mediated by innate and acquired immunity (Tan
et al., 1999a,b, 2002a; Town et al., 2001, 2005a,b, 2008; Townsend
et al., 2005; Hawkes and McLaurin, 2009). Thus, it has previously
been suggested that innate immune responses, possibly triggered
by TLR activation, play a role in the AD-associated neuroinflam-
mation (Fassbender et al., 2004; Fiala et al., 2007; Walter et al., 2007;
Malm et al., 2010; Liu et al., 2012; Saresella et al., 2014). Notably,
in AD patients T cell in peripheral blood and infiltrating the brain
are indeed activated and display memory phenotype (Shalit et al.,
1995; Lombardi et al., 1999, 2004; Tan et al., 2002b; Togo et al.,
2002); levels of IL-6 in plasma (Singh and Guthikonda, 1997), aug-
mented production of IFN-γ and TNF-α by natural killer (NK)
cells (Solerte et al., 2000), and an increase in IL-1β associated with
a concomitant decrease in IL-10 have been observed in AD (Arosio
et al., 2004).
Activated T lymphocytes can nevertheless also mediate neuro-
protection and promote neurogenesis by secreting BDNF. BDNF
production was increased in aMCI; these results are is in line with
data showing higher BDNF serum levels in preclinical stages of
Alzheimer’s disease (Laske et al., 2006; Angelucci et al., 2010) and
with post-mortem examinations of AD brains indicating a signifi-
cant increase of BDNF concentration in hippocampus and parietal
cortex (Durany et al., 2000) and of its receptor TrkB in astrocytes
and senile plaques (Connor et al., 1997). BDNF was recently sug-
gested to also mediate neurodegeneration secondarily to its ability
to induce nitric oxide production by astrocytes (Colombo et al.,
2012). Nevertheless, the observation that in aMCI a correlation was
detected between BDNF and preserved brain morphology seems
to confirm a protective role for this cytokine. Notably, the cor-
relations between MRI parameters and BDNF secreting immune
cells were lost in AD in whom, instead, brain atrophy was posi-
tively correlated with IL-21-producing CD4+ T cells. This seems
biologically important considering that IL-21 is a potent proin-
flammatory cytokine that plays a role in autoimmunity, including
multiple sclerosis, and whose biological properties include the pro-
liferation of T cells proliferation, the stimulation of NK activity,
and the functional dampening of T reg cells (Leonard and Spolski,
2005; Spolski and Leonard, 2008; Raveney et al., 2013). Confirming
the presence of inflammation is AD are also the results indicat-
ing that TH1-driven IFNγ production by T-bet-expressing (TH1)
CD8+ T lymphocytes was detected in these patients.
The preservation of brain morphology seen in aMCI was posi-
tively correlated with PD-L1 expressing CD14+ cells as well. PD-
L1 binds PD-1 and this interaction dampens immune responses,
harnessing inflammation. Recent results showed that the expres-
sion of these molecules is significantly reduced in AD and aMCI,
thus, in these diseases, fewer PD-1-expressing CD4+ T cells bind
reduced quantities of PD-L1 molecules on the surface of CD14+
APC. The interaction between PD-1 and PD-L1 regulates the reci-
procal balance between T cell tolerance and activation, and recent
data show that when PD-1 is engaged, the earliest events in T cell
activation are blocked (Parry et al., 2005), indicating that PD-1
is a highly effective negative regulator of T-cell activation even
when modestly expressed on T cell surface (Riley, 2009). Liga-
tion of PD-L1 limits effectors’ cells responses and prevents the
triggering of immune-mediated tissue damage (Selenko-Gebauer
et al., 2003; Keir et al., 2007; Sharpe et al., 2007). This antigen-
specific phenomenon is achieved via the generation of IL-10, a
powerful inflammation-dampening cytokine, and/or by the limi-
tation of the proliferation of antigen-specific cells secondarily to
the apoptosis of such cells (Dong et al., 2002; Dong and Chen,
2003; Trabattoni et al., 2003). IL-10 was comparable in AD and
aMCI, suggesting that modulation of apoptosis could be mech-
anism associated with the preservation of brain tissues seen in
aMCI. The positive correlations seen in these individuals between
CC2 and CC3 and PD-L1 expressing immune cells could specula-
tively be justified as follows: more Aβ specific cells would undergo
apoptosis secondarily to more frequent PD-1/PD-L1 interactions;
this would results in a reduced degree of neuroinflammation and,
as a consequence, a better preservation of cortical architectures.
This mechanism is lost in AD, leading to impairments of such
structures.
These immunological results stem from analyses performed on
circulating immune cells, in the attempt to define immunologic
diagnostic and prognostic correlates of disease that would be eas-
ily monitored and reproduced. The fact that we used peripheral
blood lymphocytes instead than cells circulating in the cerebro-
spinal fluid (CSF) could apparently weaken our results. Because
of ethical constrains, CSF examination could be performed in
our patients only when necessary to exclude reversible causes of
dementia. Nevertheless, the observations that immune cells con-
tinuously re-circulate throughout the body and migrate across the
blood-brain barrier (BBB), and that such barrier is permeable to
cytokines, lend support to our results.
In conclusion, the results herein seem to support the hypothesis
that a disconnection syndrome in aMCI and AD could corre-
lates with WM myelin breakdown caused by a neuroinflammation
as pathophysiological substrate. The combination of DTI and
neuroinflammation parameters might define possible surrogate
biomarkers that could be useful in longitudinal studies and in
clinical and pharmacological trials.
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